StockData

Ensysce Biosciences vs Kyntra Bio

ENSC and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENSC and KYNB compare

Kyntra Bio is the larger company, worth 1.6 times as much as Ensysce Biosciences ($13.0M against $8.0M).

Kyntra Bio grew revenue faster over the last twelve months (−37.1% versus −39.3% for Ensysce Biosciences).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENSCKYNB
Size and price
Market cap$8.0M$13.0M
Share price$0.409$3.20
Change, 1 year−80.2%−64.7%
Change, 5 years−100.0%−98.9%
Beta (5Y)3.681.52
Employees834
StockData Score
Total score55
Valuation score12 (better)
Growth score1 (better)0
Performance score02 (better)
Health score3 (better)1
Dividend score00
Valuation
P/E–0.1×
P/S1.8× (better)2.8×
FCF yield–−294%
Growth
Revenue growth (TTM)−39.3%−37.1% (better)
Revenue growth, 5Y average5.2% (better)−48.4%
Profitability
Gross margin–6.3%
Operating margin−281% (better)−1090%
Net margin–3968%
FCF margin–−824%
Financial health
Interest coverage−791.6×−5.4× (better)
Current ratio0.702.69 (better)
Altman Z-score−80.97−24.48 (better)
Piotroski F-score–5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions4.7%24.7%
Held by insiders6.2%15.7%
Insider net buying, 12 months$444K (better)$39.7K
Short interest, % of float0.49%2.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.